| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Bone Density | 8 | 2018 | 335 | 1.54 | Why? |
| Bone and Bones | 3 | 2018 | 235 | 1.35 | Why? |
| Muscle, Skeletal | 5 | 2018 | 915 | 1.34 | Why? |
| Polymyalgia Rheumatica | 3 | 2018 | 64 | 1.18 | Why? |
| Bone Density Conservation Agents | 4 | 2018 | 209 | 1.11 | Why? |
| Muscle Strength | 3 | 2018 | 317 | 0.82 | Why? |
| Osteoporosis | 7 | 2021 | 410 | 0.76 | Why? |
| Body Composition | 3 | 2018 | 414 | 0.67 | Why? |
| Sarcopenia | 3 | 2018 | 422 | 0.59 | Why? |
| Osteoporotic Fractures | 2 | 2018 | 175 | 0.57 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.54 | Why? |
| Hand Strength | 3 | 2018 | 202 | 0.51 | Why? |
| Enterobacteriaceae Infections | 1 | 2018 | 529 | 0.47 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.45 | Why? |
| Arthritis, Rheumatoid | 4 | 2020 | 2043 | 0.40 | Why? |
| Infant, Low Birth Weight | 1 | 2011 | 243 | 0.39 | Why? |
| Porphyria, Acute Intermittent | 1 | 2018 | 3 | 0.39 | Why? |
| Actinomycetales Infections | 1 | 2018 | 10 | 0.38 | Why? |
| Microscopic Angioscopy | 1 | 2018 | 58 | 0.38 | Why? |
| Child Development | 2 | 2017 | 352 | 0.37 | Why? |
| Stomach Diseases | 1 | 2018 | 27 | 0.36 | Why? |
| Arthritis, Psoriatic | 4 | 2018 | 625 | 0.35 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1458 | 0.35 | Why? |
| Bone Development | 1 | 2017 | 8 | 0.35 | Why? |
| Spondylarthritis | 2 | 2020 | 174 | 0.35 | Why? |
| HIV Infections | 14 | 2019 | 11620 | 0.34 | Why? |
| Tenosynovitis | 2 | 2001 | 22 | 0.34 | Why? |
| Drug Resistance, Viral | 2 | 2018 | 1083 | 0.33 | Why? |
| Anemia, Refractory, with Excess of Blasts | 1 | 2006 | 2 | 0.33 | Why? |
| Anti-HIV Agents | 7 | 2018 | 2209 | 0.31 | Why? |
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2006 | 55 | 0.31 | Why? |
| HIV-1 | 7 | 2018 | 3365 | 0.31 | Why? |
| Natalizumab | 1 | 2017 | 144 | 0.31 | Why? |
| Myositis | 1 | 2018 | 185 | 0.30 | Why? |
| Fractures, Bone | 4 | 2007 | 487 | 0.30 | Why? |
| Vision Disorders | 1 | 2018 | 260 | 0.28 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 952 | 0.28 | Why? |
| Magnetic Resonance Imaging | 4 | 2018 | 6551 | 0.28 | Why? |
| Central Nervous System Diseases | 1 | 2020 | 410 | 0.28 | Why? |
| Antirheumatic Agents | 4 | 2020 | 3023 | 0.27 | Why? |
| Societies, Scientific | 1 | 2017 | 414 | 0.27 | Why? |
| Pulmonary Artery | 1 | 2021 | 803 | 0.26 | Why? |
| White Matter | 1 | 2017 | 369 | 0.26 | Why? |
| Vascular Stiffness | 1 | 2017 | 264 | 0.26 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.26 | Why? |
| Nerve Fibers, Myelinated | 1 | 2012 | 11 | 0.25 | Why? |
| Accidental Falls | 1 | 2017 | 448 | 0.24 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 533 | 0.24 | Why? |
| Immune System Diseases | 1 | 2017 | 410 | 0.24 | Why? |
| DNA Methylation | 1 | 2017 | 688 | 0.24 | Why? |
| Visual Acuity | 1 | 2018 | 790 | 0.23 | Why? |
| Arthritis | 1 | 2006 | 288 | 0.23 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.23 | Why? |
| Health Literacy | 1 | 2021 | 1078 | 0.22 | Why? |
| Communicable Diseases, Emerging | 2 | 2017 | 2523 | 0.22 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2017 | 2483 | 0.22 | Why? |
| Calcium | 1 | 2016 | 708 | 0.22 | Why? |
| Computed Tomography Angiography | 1 | 2021 | 2153 | 0.21 | Why? |
| Neoplasm Proteins | 1 | 2006 | 501 | 0.21 | Why? |
| Standard of Care | 1 | 2017 | 1297 | 0.21 | Why? |
| Aged | 34 | 2021 | 215776 | 0.20 | Why? |
| Lung Diseases, Interstitial | 1 | 2020 | 1476 | 0.19 | Why? |
| Venous Thromboembolism | 1 | 2017 | 4273 | 0.19 | Why? |
| Vasculitis | 1 | 2006 | 691 | 0.19 | Why? |
| Age of Onset | 3 | 2019 | 557 | 0.19 | Why? |
| Aging | 3 | 2017 | 3581 | 0.19 | Why? |
| Lewy Body Disease | 1 | 2018 | 36 | 0.19 | Why? |
| Rheumatology | 2 | 2009 | 1213 | 0.19 | Why? |
| Genetic Background | 1 | 2017 | 11 | 0.19 | Why? |
| Alendronate | 1 | 2017 | 12 | 0.18 | Why? |
| Teriparatide | 1 | 2017 | 16 | 0.18 | Why? |
| Femur Neck | 2 | 2018 | 29 | 0.18 | Why? |
| Mucormycosis | 1 | 2018 | 832 | 0.18 | Why? |
| Sex Ratio | 1 | 2018 | 69 | 0.18 | Why? |
| Walking Speed | 1 | 2018 | 77 | 0.18 | Why? |
| Humans | 80 | 2021 | 930598 | 0.18 | Why? |
| Denosumab | 1 | 2017 | 49 | 0.17 | Why? |
| Kidney Transplantation | 2 | 2018 | 5397 | 0.17 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.17 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.17 | Why? |
| Edema | 1 | 2001 | 333 | 0.17 | Why? |
| Thiophenes | 1 | 2017 | 78 | 0.17 | Why? |
| Absorptiometry, Photon | 2 | 2018 | 168 | 0.17 | Why? |
| Organizations | 1 | 2009 | 201 | 0.17 | Why? |
| Osteoporosis, Postmenopausal | 1 | 2007 | 75 | 0.17 | Why? |
| Diphosphonates | 1 | 2017 | 121 | 0.17 | Why? |
| France | 11 | 2021 | 12074 | 0.16 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.16 | Why? |
| Hypersensitivity | 1 | 2017 | 1137 | 0.16 | Why? |
| Anthropometry | 2 | 2018 | 233 | 0.16 | Why? |
| Receptors, Interleukin-2 | 2 | 1994 | 115 | 0.16 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.16 | Why? |
| beta-Lactam Resistance | 1 | 2018 | 150 | 0.16 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 1439 | 0.16 | Why? |
| Virus Latency | 1 | 2018 | 251 | 0.16 | Why? |
| Female | 46 | 2021 | 380317 | 0.16 | Why? |
| Urologic Neoplasms | 1 | 2021 | 348 | 0.16 | Why? |
| Pulmonary Embolism | 2 | 2021 | 4775 | 0.16 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2017 | 1475 | 0.16 | Why? |
| Male | 43 | 2021 | 367725 | 0.16 | Why? |
| Lumbar Vertebrae | 2 | 2018 | 196 | 0.15 | Why? |
| Biological Factors | 1 | 2009 | 276 | 0.15 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.15 | Why? |
| Glucocorticoids | 4 | 2018 | 4431 | 0.15 | Why? |
| Cognitive Dysfunction | 1 | 2017 | 1389 | 0.15 | Why? |
| Birth Weight | 1 | 2007 | 250 | 0.15 | Why? |
| Cohort Studies | 10 | 2021 | 36005 | 0.15 | Why? |
| Etanercept | 2 | 2017 | 162 | 0.15 | Why? |
| Frailty | 1 | 2017 | 1432 | 0.15 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.15 | Why? |
| Auranofin | 1 | 1994 | 37 | 0.14 | Why? |
| Immunocompromised Host | 2 | 2018 | 5150 | 0.14 | Why? |
| Dietary Supplements | 1 | 2016 | 2251 | 0.13 | Why? |
| Hip Dislocation, Congenital | 1 | 2003 | 9 | 0.13 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.13 | Why? |
| Multimorbidity | 1 | 2019 | 703 | 0.13 | Why? |
| Depression | 2 | 2018 | 14116 | 0.13 | Why? |
| Cardiovascular Agents | 1 | 2009 | 663 | 0.13 | Why? |
| Metabolome | 1 | 2018 | 624 | 0.13 | Why? |
| Hip Joint | 1 | 2003 | 59 | 0.13 | Why? |
| Middle Aged | 30 | 2021 | 270681 | 0.13 | Why? |
| Urologic Diseases | 1 | 2021 | 860 | 0.12 | Why? |
| Body Height | 2 | 2017 | 100 | 0.12 | Why? |
| Osteoarthritis, Hip | 1 | 2003 | 56 | 0.12 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.12 | Why? |
| Symptom Flare Up | 2 | 2020 | 432 | 0.12 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.12 | Why? |
| Cyclosporine | 2 | 1998 | 449 | 0.12 | Why? |
| Community-Acquired Infections | 1 | 2015 | 2328 | 0.12 | Why? |
| Lymphoma | 1 | 2017 | 522 | 0.12 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 1454 | 0.12 | Why? |
| Infliximab | 2 | 2017 | 502 | 0.12 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.12 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.11 | Why? |
| Leukemia | 1 | 2017 | 598 | 0.11 | Why? |
| Information Dissemination | 1 | 2017 | 2986 | 0.11 | Why? |
| Inflammation | 4 | 2018 | 13255 | 0.11 | Why? |
| Viruses | 1 | 2015 | 2238 | 0.11 | Why? |
| Arthralgia | 1 | 2003 | 173 | 0.11 | Why? |
| Aged, 80 and over | 11 | 2021 | 88759 | 0.11 | Why? |
| Dyslipidemias | 1 | 2018 | 791 | 0.11 | Why? |
| Adult | 29 | 2021 | 244371 | 0.11 | Why? |
| Wrist Joint | 1 | 2000 | 34 | 0.10 | Why? |
| Suicide, Attempted | 1 | 2017 | 599 | 0.10 | Why? |
| Hearing Loss, Bilateral | 1 | 1989 | 19 | 0.10 | Why? |
| Coronary Disease | 2 | 2014 | 645 | 0.10 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.10 | Why? |
| Iodine | 1 | 2021 | 116 | 0.10 | Why? |
| Interleukin-2 | 1 | 2001 | 443 | 0.10 | Why? |
| Rhodococcus equi | 1 | 2018 | 2 | 0.10 | Why? |
| General Practitioners | 1 | 2017 | 568 | 0.10 | Why? |
| Infectious Mononucleosis | 1 | 1989 | 35 | 0.10 | Why? |
| Longitudinal Studies | 3 | 2018 | 9893 | 0.10 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.10 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.09 | Why? |
| Diagnosis, Differential | 2 | 2018 | 7220 | 0.09 | Why? |
| Gene Amplification | 1 | 1998 | 85 | 0.09 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.09 | Why? |
| Primary Health Care | 2 | 2017 | 4839 | 0.09 | Why? |
| Pulmonary Circulation | 1 | 2021 | 207 | 0.09 | Why? |
| Microsporida | 1 | 1997 | 2 | 0.09 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.09 | Why? |
| Microsporidiosis | 1 | 1997 | 7 | 0.09 | Why? |
| Bipolar Disorder | 1 | 2017 | 744 | 0.09 | Why? |
| Alzheimer Disease | 1 | 2018 | 1020 | 0.09 | Why? |
| Knee Joint | 1 | 2000 | 194 | 0.09 | Why? |
| GATA3 Transcription Factor | 1 | 2017 | 16 | 0.09 | Why? |
| Systems Integration | 1 | 2017 | 72 | 0.09 | Why? |
| Papillomavirus Vaccines | 1 | 2013 | 405 | 0.09 | Why? |
| Osteoarthritis | 1 | 2000 | 205 | 0.09 | Why? |
| Body Size | 1 | 2017 | 20 | 0.09 | Why? |
| Intestinal Diseases, Parasitic | 1 | 1997 | 34 | 0.09 | Why? |
| Glatiramer Acetate | 1 | 2017 | 35 | 0.09 | Why? |
| Levofloxacin | 1 | 2018 | 115 | 0.09 | Why? |
| Geriatric Assessment | 2 | 2011 | 1372 | 0.08 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.08 | Why? |
| Range of Motion, Articular | 1 | 2018 | 168 | 0.08 | Why? |
| Adiponectin | 1 | 2018 | 123 | 0.08 | Why? |
| Toll-Like Receptor 4 | 1 | 2020 | 390 | 0.08 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.08 | Why? |
| Tumor Necrosis Factor Decoy Receptors | 1 | 2006 | 2 | 0.08 | Why? |
| Leptin | 1 | 2018 | 141 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Neurologists | 1 | 2020 | 283 | 0.08 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.08 | Why? |
| Ecology | 1 | 2017 | 140 | 0.08 | Why? |
| Systole | 1 | 2017 | 252 | 0.08 | Why? |
| Mental Status and Dementia Tests | 1 | 2017 | 208 | 0.08 | Why? |
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 40 | 0.08 | Why? |
| Postal Service | 1 | 1997 | 88 | 0.08 | Why? |
| Amphotericin B | 1 | 2018 | 256 | 0.08 | Why? |
| Case-Control Studies | 6 | 2018 | 17671 | 0.08 | Why? |
| Cell Lineage | 1 | 2017 | 241 | 0.08 | Why? |
| CpG Islands | 1 | 2017 | 230 | 0.08 | Why? |
| Pulse Wave Analysis | 1 | 2017 | 221 | 0.08 | Why? |
| Kidney Calculi | 1 | 2016 | 62 | 0.08 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Parkinson Disease | 1 | 2018 | 1414 | 0.08 | Why? |
| Treatment Outcome | 6 | 2018 | 51732 | 0.08 | Why? |
| Practice Guidelines as Topic | 3 | 2018 | 15421 | 0.08 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2017 | 8843 | 0.07 | Why? |
| Diet | 1 | 2018 | 2052 | 0.07 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.07 | Why? |
| Psoriasis | 1 | 2009 | 1739 | 0.07 | Why? |
| Hearing Loss | 1 | 1989 | 225 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2012 | 7972 | 0.07 | Why? |
| Risk Assessment | 5 | 2018 | 25439 | 0.07 | Why? |
| Substance Withdrawal Syndrome | 1 | 2017 | 137 | 0.07 | Why? |
| Umbilical Cord | 1 | 2017 | 358 | 0.07 | Why? |
| Lung | 2 | 2021 | 31049 | 0.07 | Why? |
| Papillomavirus Infections | 1 | 2013 | 861 | 0.07 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 1997 | 260 | 0.07 | Why? |
| Software | 1 | 2017 | 2501 | 0.07 | Why? |
| Patient Admission | 2 | 2021 | 5250 | 0.07 | Why? |
| Injections, Intra-Articular | 2 | 2018 | 104 | 0.07 | Why? |
| Contrast Media | 1 | 2021 | 1011 | 0.07 | Why? |
| Risk Factors | 10 | 2019 | 71621 | 0.07 | Why? |
| Brain | 1 | 2012 | 5133 | 0.07 | Why? |
| Causality | 1 | 2018 | 857 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.07 | Why? |
| Pain | 2 | 2018 | 1084 | 0.07 | Why? |
| Geriatric Psychiatry | 1 | 2017 | 208 | 0.07 | Why? |
| beta-Thalassemia | 1 | 2017 | 200 | 0.07 | Why? |
| United Kingdom | 4 | 2017 | 18046 | 0.07 | Why? |
| Physical Fitness | 1 | 1997 | 334 | 0.07 | Why? |
| Lymphoma, AIDS-Related | 1 | 2003 | 13 | 0.07 | Why? |
| Interleukin-6 | 1 | 2012 | 7522 | 0.07 | Why? |
| Triazoles | 1 | 2018 | 440 | 0.06 | Why? |
| Paris | 1 | 2017 | 1287 | 0.06 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.06 | Why? |
| Idiopathic Pulmonary Fibrosis | 1 | 2020 | 595 | 0.06 | Why? |
| Electronic Health Records | 1 | 2017 | 3492 | 0.06 | Why? |
| Drug Resistance | 1 | 2006 | 395 | 0.06 | Why? |
| Mass Vaccination | 1 | 2013 | 1101 | 0.06 | Why? |
| Italy | 4 | 2019 | 38444 | 0.06 | Why? |
| Adalimumab | 1 | 2017 | 389 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.06 | Why? |
| Skin Diseases | 1 | 2009 | 2509 | 0.06 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 2426 | 0.06 | Why? |
| Muscles | 1 | 2013 | 152 | 0.06 | Why? |
| Recurrence | 2 | 2017 | 3675 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.06 | Why? |
| Greece | 2 | 2020 | 2091 | 0.06 | Why? |
| Spatio-Temporal Analysis | 1 | 2018 | 1182 | 0.06 | Why? |
| Infant, Newborn | 4 | 2017 | 23105 | 0.06 | Why? |
| Sarcoma, Kaposi | 1 | 2003 | 97 | 0.06 | Why? |
| Atrophy | 1 | 2012 | 192 | 0.06 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.06 | Why? |
| Triage | 1 | 2021 | 7151 | 0.06 | Why? |
| Interleukin-10 | 1 | 2018 | 1409 | 0.05 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.05 | Why? |
| Incidence | 6 | 2018 | 25622 | 0.05 | Why? |
| Treatment Failure | 2 | 2017 | 2106 | 0.05 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.05 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.05 | Why? |
| Muscle Strength Dynamometer | 1 | 2009 | 11 | 0.05 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 529 | 0.05 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2018 | 7268 | 0.05 | Why? |
| Residence Characteristics | 1 | 2011 | 1927 | 0.05 | Why? |
| Time Factors | 7 | 2018 | 31397 | 0.05 | Why? |
| Autoimmune Diseases | 1 | 2013 | 1996 | 0.05 | Why? |
| Child | 5 | 2018 | 70012 | 0.05 | Why? |
| Hippocampus | 1 | 2012 | 237 | 0.05 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.05 | Why? |
| Musculoskeletal Diseases | 1 | 1997 | 646 | 0.05 | Why? |
| Meta-Analysis as Topic | 1 | 2016 | 1289 | 0.05 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.05 | Why? |
| Tomography, X-Ray Computed | 3 | 2018 | 25144 | 0.05 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.05 | Why? |
| Climate Change | 1 | 2017 | 901 | 0.05 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2003 | 403 | 0.05 | Why? |
| Dermatitis, Atopic | 1 | 2017 | 714 | 0.05 | Why? |
| Spain | 1 | 2017 | 15545 | 0.05 | Why? |
| Tricarboxylic Acids | 1 | 2018 | 2 | 0.05 | Why? |
| Hypoxanthine | 1 | 2018 | 5 | 0.05 | Why? |
| Follow-Up Studies | 4 | 2017 | 17020 | 0.05 | Why? |
| Inosine | 1 | 2018 | 9 | 0.05 | Why? |
| Infection Control | 1 | 2017 | 23131 | 0.05 | Why? |
| Adrenal Cortex Hormones | 2 | 2018 | 6537 | 0.05 | Why? |
| Prevalence | 4 | 2019 | 25773 | 0.04 | Why? |
| Regression Analysis | 2 | 2014 | 2484 | 0.04 | Why? |
| Carnitine | 1 | 2018 | 47 | 0.04 | Why? |
| Cognition | 1 | 2017 | 1394 | 0.04 | Why? |
| Diet Surveys | 1 | 2018 | 152 | 0.04 | Why? |
| Myocardial Infarction | 1 | 2014 | 3361 | 0.04 | Why? |
| Hypertension | 1 | 2009 | 8895 | 0.04 | Why? |
| Leukemia, Biphenotypic, Acute | 1 | 2017 | 3 | 0.04 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.04 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.04 | Why? |
| Algorithms | 2 | 2006 | 7346 | 0.04 | Why? |
| Adolescent | 5 | 2018 | 86841 | 0.04 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.04 | Why? |
| Depressive Disorder | 1 | 2018 | 1236 | 0.04 | Why? |
| Europe | 2 | 2021 | 12702 | 0.04 | Why? |
| HIV Reverse Transcriptase | 1 | 2017 | 104 | 0.04 | Why? |
| Memory | 1 | 2018 | 137 | 0.04 | Why? |
| Porphyrins | 1 | 2018 | 88 | 0.04 | Why? |
| Organizational Objectives | 1 | 2009 | 180 | 0.04 | Why? |
| Immunoglobulin Light Chains | 1 | 2017 | 62 | 0.04 | Why? |
| Lymphocyte Transfusion | 1 | 2017 | 26 | 0.04 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.04 | Why? |
| HIV Protease | 1 | 2017 | 86 | 0.04 | Why? |
| Cross-Sectional Studies | 6 | 2019 | 53120 | 0.04 | Why? |
| Interview, Psychological | 1 | 2017 | 68 | 0.04 | Why? |
| Medication Therapy Management | 1 | 2020 | 312 | 0.04 | Why? |
| Lipids | 1 | 2004 | 1079 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.04 | Why? |
| Indinavir | 2 | 2004 | 27 | 0.04 | Why? |
| Infant | 2 | 2018 | 30274 | 0.04 | Why? |
| Fatty Acids | 1 | 2018 | 238 | 0.04 | Why? |
| Quality of Life | 1 | 2007 | 9820 | 0.04 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.04 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.04 | Why? |
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 184 | 0.04 | Why? |
| Middle East | 1 | 2021 | 1418 | 0.04 | Why? |
| Cities | 1 | 2017 | 4937 | 0.04 | Why? |
| Risk | 1 | 2017 | 5288 | 0.04 | Why? |
| Prenatal Diagnosis | 1 | 1998 | 345 | 0.04 | Why? |
| Methylprednisolone | 1 | 2006 | 2107 | 0.04 | Why? |
| Lymphatic Diseases | 1 | 1985 | 96 | 0.04 | Why? |
| Blood Donors | 1 | 1998 | 2956 | 0.04 | Why? |
| Binding Sites | 1 | 2017 | 6201 | 0.03 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.03 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.03 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 31 | 0.03 | Why? |
| International Classification of Diseases | 1 | 2017 | 265 | 0.03 | Why? |
| Bayes Theorem | 2 | 2017 | 3237 | 0.03 | Why? |
| Rheumatologists | 1 | 2018 | 346 | 0.03 | Why? |
| Therapeutic Irrigation | 2 | 2000 | 167 | 0.03 | Why? |
| Transplantation, Homologous | 1 | 2017 | 757 | 0.03 | Why? |
| Age Factors | 3 | 2017 | 21039 | 0.03 | Why? |
| Asia | 1 | 2021 | 2399 | 0.03 | Why? |
| Coinfection | 2 | 2018 | 6820 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Azithromycin | 1 | 2018 | 3943 | 0.03 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.03 | Why? |
| England | 2 | 2009 | 5116 | 0.03 | Why? |
| Alphapapillomavirus | 1 | 2013 | 107 | 0.03 | Why? |
| History, 20th Century | 1 | 2009 | 1282 | 0.03 | Why? |
| Didanosine | 1 | 2001 | 3 | 0.03 | Why? |
| CD4 Lymphocyte Count | 2 | 2003 | 1517 | 0.03 | Why? |
| Dermatologists | 1 | 2018 | 435 | 0.03 | Why? |
| Women's Health | 1 | 2007 | 444 | 0.03 | Why? |
| Fatigue | 1 | 2013 | 2479 | 0.03 | Why? |
| Purines | 1 | 2018 | 816 | 0.03 | Why? |
| Zidovudine | 1 | 2001 | 63 | 0.03 | Why? |
| Occupational Diseases | 1 | 1997 | 2787 | 0.03 | Why? |
| Hemoglobins | 1 | 2018 | 958 | 0.03 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.03 | Why? |
| Transplant Recipients | 1 | 2018 | 4982 | 0.03 | Why? |
| Models, Biological | 1 | 1999 | 4907 | 0.03 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 1999 | 5164 | 0.03 | Why? |
| Chemokines | 1 | 1998 | 1095 | 0.03 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.03 | Why? |
| Surveys and Questionnaires | 4 | 2021 | 43792 | 0.03 | Why? |
| Gastrointestinal Diseases | 1 | 2016 | 2580 | 0.03 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 526 | 0.03 | Why? |
| Connective Tissue Diseases | 1 | 2013 | 187 | 0.03 | Why? |
| Body Weight | 1 | 2007 | 1074 | 0.03 | Why? |
| Cyclooxygenase Inhibitors | 1 | 2000 | 46 | 0.03 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.03 | Why? |
| Joints | 1 | 1992 | 97 | 0.03 | Why? |
| Switzerland | 1 | 2009 | 2738 | 0.03 | Why? |
| Vitamin D | 1 | 2016 | 2904 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2009 | 1530 | 0.03 | Why? |
| Solubility | 1 | 1992 | 382 | 0.03 | Why? |
| Stroke | 1 | 2014 | 8839 | 0.03 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.03 | Why? |
| Numerical Analysis, Computer-Assisted | 1 | 1999 | 30 | 0.02 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2001 | 309 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Pregnancy | 3 | 2017 | 23879 | 0.02 | Why? |
| Hyaluronic Acid | 1 | 2000 | 168 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Neoplasms | 1 | 2017 | 17251 | 0.02 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.02 | Why? |
| Airway Obstruction | 1 | 2001 | 182 | 0.02 | Why? |
| Pensions | 1 | 1997 | 11 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2017 | 21571 | 0.02 | Why? |
| Health Care Surveys | 1 | 2018 | 2942 | 0.02 | Why? |
| Patient Compliance | 1 | 2007 | 1468 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Markov Chains | 1 | 1999 | 502 | 0.02 | Why? |
| Administration, Oral | 1 | 1994 | 2340 | 0.02 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.02 | Why? |
| Acupuncture Therapy | 1 | 2000 | 234 | 0.02 | Why? |
| Antibodies, Monoclonal | 1 | 2006 | 8041 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2013 | 11304 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Analgesics | 1 | 2000 | 451 | 0.02 | Why? |
| Etidronic Acid | 1 | 1995 | 3 | 0.02 | Why? |
| Statistics, Nonparametric | 1 | 1999 | 1008 | 0.02 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.02 | Why? |
| Nasopharynx | 1 | 2015 | 10224 | 0.02 | Why? |
| International Cooperation | 1 | 2009 | 3436 | 0.02 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2013 | 645 | 0.02 | Why? |
| Radiography | 1 | 2003 | 1576 | 0.02 | Why? |
| Weight Loss | 1 | 2000 | 826 | 0.02 | Why? |
| Administration, Inhalation | 1 | 2001 | 1647 | 0.02 | Why? |
| Saquinavir | 1 | 2004 | 34 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2017 | 4155 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2013 | 10649 | 0.02 | Why? |
| HIV Protease Inhibitors | 1 | 1997 | 434 | 0.02 | Why? |
| Remission Induction | 1 | 1997 | 950 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Spinal Fractures | 1 | 1995 | 124 | 0.02 | Why? |
| Calcitonin | 1 | 1995 | 201 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 1992 | 3776 | 0.01 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Estrogens | 1 | 1995 | 252 | 0.01 | Why? |
| Health Surveys | 2 | 1998 | 2841 | 0.01 | Why? |
| Palliative Care | 1 | 2017 | 2665 | 0.01 | Why? |
| Lung Diseases | 1 | 1985 | 2361 | 0.01 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.01 | Why? |
| Physical Therapy Modalities | 1 | 2000 | 1090 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.01 | Why? |
| Triglycerides | 1 | 2004 | 478 | 0.01 | Why? |
| DNA, Viral | 1 | 2001 | 2521 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Ritonavir | 2 | 2004 | 4212 | 0.01 | Why? |
| Patient Education as Topic | 1 | 2000 | 1476 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Cholesterol | 1 | 2004 | 660 | 0.01 | Why? |
| Immunologic Memory | 1 | 2001 | 3362 | 0.01 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2013 | 1969 | 0.01 | Why? |
| Macrophage Inflammatory Proteins | 1 | 1998 | 14 | 0.01 | Why? |
| Blood Transfusion | 1 | 1998 | 1399 | 0.01 | Why? |
| Chemokine CCL4 | 1 | 1998 | 71 | 0.01 | Why? |
| Mass Screening | 1 | 1998 | 8005 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Multiple Sclerosis | 1 | 2013 | 2600 | 0.01 | Why? |
| Chemokine CCL5 | 1 | 1998 | 169 | 0.01 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2001 | 4545 | 0.01 | Why? |
| Logistic Models | 2 | 2004 | 9089 | 0.01 | Why? |
| Chemokine CCL2 | 1 | 1998 | 389 | 0.01 | Why? |
| Mycobacterium Infections | 1 | 1985 | 72 | 0.01 | Why? |
| Drug Approval | 1 | 1995 | 1325 | 0.01 | Why? |
| Treatment Refusal | 1 | 1998 | 211 | 0.01 | Why? |
| Diarrhea | 1 | 1997 | 2743 | 0.01 | Why? |
| Workplace | 1 | 1997 | 2075 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 1999 | 6740 | 0.01 | Why? |
| Risk-Taking | 1 | 1998 | 508 | 0.01 | Why? |
| Asthma | 1 | 2001 | 4383 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 1998 | 11559 | 0.01 | Why? |
| Interleukin-8 | 1 | 1998 | 964 | 0.01 | Why? |
| Abortion, Induced | 1 | 1998 | 437 | 0.01 | Why? |
| Pneumonia, Pneumocystis | 1 | 1985 | 322 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2018 | 23402 | 0.01 | Why? |
| Pulmonary Alveoli | 1 | 1985 | 867 | 0.01 | Why? |
| Cytomegalovirus Infections | 1 | 1985 | 667 | 0.01 | Why? |
| Attitude to Health | 1 | 1998 | 2002 | 0.00 | Why? |
| Patient Acceptance of Health Care | 1 | 1998 | 5002 | 0.00 | Why? |
| Animals | 1 | 1997 | 78931 | 0.00 | Why? |
| Health Policy | 1 | 1998 | 6242 | 0.00 | Why? |
| Antibodies, Viral | 1 | 1999 | 51949 | 0.00 | Why? |
| Health Services Accessibility | 1 | 1998 | 10697 | 0.00 | Why? |